Management and outcomes of surgical patients with intestinal Behçet’s disease and Crohn’s disease in southwest China

Table 3 Use of drugs before and after surgery in patients with gastrointestinal involvement in Behçet's disease and Crohn’s disease

	GIBD (n = 10)			CD (n = 106)		P value
	Before surgery (n = 3)1	After surgery (n = 10)	Before surgery (n = 50)2		After surgery (n = 106)	P1 value	P2 value
5-ASA or sulfasalazine	1(33.3)	1 (10)	31 (62)		12 (11.3)	0.555	1.000
AZA or 6-MP	1(33.3)	6 (60)	20 (40)		74 (69.8)	1.000	0.498
Corticosteroids	0	6 (60)	7 (14)		7 (6.6)	1.000	< 0.001
Biological agent	0	2 (20)	9 (18)		27 (25.5)	1.000	1.000
Infliximab	0	0	9 (18)		27 (25.5)	1.000	0.114
Adalimumab	0	2 (20)	0		0	-	0.007
Thalidomide	1(33.3)	7 (70)	2 (4)		9 (8.5)	0.163	< 0.001
MTX	0	0	1 (2)		2 (1.9)	1.000	1.000
Others	0	1 (10)	1 (2)		2 (1.9)	1.000	0.239

¹Three (30.0) surgical patients with gastrointestinal involvement in Behçet's disease were diagnosed before first surgery.

²Fifty (45.0) surgical patients with Crohn’s disease were diagnosed before first surgery. CD: Crohn’s disease; GIBD: Gastrointestinal involvement in Behçet's disease; 5-ASA: 5-aminosallcylic acid; 6-MP: 6-mercaptopurine; AZA: Azathioprine; MTX: Methotrexate.